MAOB and Alzheimer disease: The lack of a cognitive effect in moderate AD is consistent with the effect of the MAO-B inhibitor, selegiline, which showed no long-term benefit on cognition in patients with moderate-to-severe AD [11]; rather, a treatment effect has been observed only in 4–6- or 8–17-week studies [27].